FHL3抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse skeletal muscle tissue, Primary antibody: P01378(FHL3 Antibody) at dilution 1/1600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P01378(FHL3 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P01378(FHL3 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of FHL3 Antibody**

The FHL3 (Four and a Half LIM Domains 3) antibody is a tool used to detect and study the FHL3 protein, a member of the four-and-a-half-LIM-only protein family. FHL3 contains four LIM domains and a half-LIM motif, which mediate protein-protein interactions and regulate cellular processes like signaling, proliferation, and differentiation. Primarily expressed in skeletal muscle, heart, and certain cancer tissues, FHL3 functions as a transcriptional co-regulator, interacting with transcription factors (e.g., MyoD, Runx2) and modulating pathways involved in muscle development, osteogenesis, and tumor progression.

Research highlights its dual roles in cancer: FHL3 can act as a tumor suppressor (e.g., inhibiting gastric or liver cancer growth) or promoter (e.g., enhancing colorectal cancer metastasis), depending on cellular context. Its involvement in muscle regeneration and fibrosis also makes it relevant in muscular dystrophy and cardiovascular studies.

The FHL3 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and interactions. Validating antibody specificity is critical due to homology among FHL family members. Recent studies explore FHL3’s potential as a diagnostic biomarker or therapeutic target, emphasizing its context-dependent roles in health and disease.